Kursprognose für Urogen Pharma Ltd (URGN)URGNUrogen Pharma Ltd

Alphio's URGN stock price prediction model matches the current Urogen Pharma Ltd tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $33.78 (+0.10%). The 1-week path is $34.01 (+0.76%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

UroGen Pharma is currently a hold. The stock is trading at $34.49, significantly below the average analyst price target of $60, suggesting potential for upside. However, the RSI is at 28.721, indicating that the stock is oversold, which could mean further downside risk. Additionally, the forward P/E ratio is 36.4964, suggesting that the stock may be overvalued based on future earnings expectations. The recent FDA acceptance of UGN-103 for bladder cancer treatment is a positive catalyst, but the stock has seen a decline of 16.59% over the past 20 days, indicating market caution. The main risk is the high forward P/E ratio, which may not justify the current price if future earnings do not meet expectations.

Urogen Pharma Ltd (URGN) last closed at $33.75, losing -0.47%. These facts feed the 1-day and 1-week URGN price prediction above.